Nevertheless, accumulating evidences suggest that CD5+ DLBCL is a distinctive subgroup which typically presents aggressive clinical features and adverse outcomes [1, 4, 7–11]. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.